PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩70 per share · Prices as of the 2026-10-02 close
Hyundai Bioland, shifting its center of gravity from cosmetic ingredients toward medical devices and health-supplement distribution, returned to profit for two consecutive quarters in the first half of 2026 after a fourth-quarter 2025 loss, though uncertainty over the controlling shareholder's stake disposal continues to weigh on its valuation.
2025 annual revenue reached KRW 130.5 billion, up year-on-year, but owners' net income plunged to KRW 253 million, reflecting high earnings volatility
After an operating loss of KRW -2.47 billion in 4Q25, the company posted consecutive operating profits in 1Q26 and 2Q26 (KRW 5.19bn and KRW 7.04bn)
Cosmetic ingredients still account for over 40% of revenue, while the medical device segment—about 15% of sales—delivers an operating margin above 30%
Exclusive domestic distribution of Nestle Health Science brands has emerged as a new growth pillar, expanding the health-supplement revenue mix
Uncertainty over how controlling shareholder Hyundai GF Holdings will handle its stake (sale, merger, etc.) could persist until 2027, keeping governance risk in play
Founded in 1995 and listed on KOSDAQ in 2001, Hyundai Bioland is a natural-material biotech company that came under the current ownership structure in 2020 when the Hyundai Department Store Group (then Hyundai HCN) acquired the stake from SK.
The business is divided into four segments—cosmetic ingredients, health-supplement ingredients and distribution, pharmaceutical ingredients, and medical devices—with cosmetic materials still accounting for over 40% of total revenue as the core business.
Major customers include Amorepacific, LG Household & Health Care, and Cosmax, with Amorepacific's share of sales having fallen from over 60% historically to roughly 20-25% today.
The medical device segment, though only about 15% of revenue, is a high-profitability area with an operating margin above 30%, centered on the dental membrane product 'OssGuide' (with Osstem Implant as a key customer) and collagen products used as wound dressings; OssGuide reportedly generates around KRW 8 billion annually while collagen products bring in roughly KRW 5-6 billion.
Since a strategic partnership with Nestle Health Science in August 2023, the company has been expanding exclusive domestic distribution of brands such as Solgar, Vital Proteins, Nuun, and Go Healthy, targeting over KRW 100 billion in this segment's sales by 2030.
The company has operated three domestic plants in Osong (cosmetics/pharmaceutical ingredients), Ansan (health supplements), and Ochang (medical devices), along with a China production base in Haimen that has reportedly been wound down due to weak performance.
While it maintains the No.1 market share in Korea's natural cosmetic-ingredient market, natural materials account for less than 2% of overall cosmetics value, and abundant substitutes limit the potential for high operating leverage in this segment.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩34.6B | ₩5.5B | 15.9% |
| 2025Q3 | ₩35.5B | ₩4.7B | 13.3% |
| 2025Q4 | ₩26.7B | -₩2.5B | −9.3% |
| 2026Q1 | ₩38.2B | ₩5.2B | 13.6% |
| 2026Q2 | ₩40.3B | ₩7B | 17.5% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩99.2B | ₩9.1B | ₩4.8B | 9.1% | 3.7% | 36.2% |
| 2023 | ₩101.7B | ₩7.1B | ₩8.1B | 7.0% | 5.9% | 35.4% |
| 2024 | ₩119.5B | ₩16.4B | ₩5.7B | 13.7% | 4.1% | 41.1% |
| 2025 | ₩130.5B | ₩12.7B | ₩300M | 9.7% | 0.2% | 22.6% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Annual revenue rose to KRW 130.5 billion in 2025 from KRW 119.5 billion in 2024, yet operating profit actually declined to KRW 12.7 billion from KRW 16.4 billion, and owners' net income collapsed to just KRW 253 million (versus KRW 5.7 billion in 2024 and KRW 8.1 billion in 2023).
A fourth-quarter 2025 operating loss of KRW -2.47 billion (net loss of KRW -1.77 billion) was the key one-off factor dragging down the full year, following a solid third quarter with revenue of KRW 35.5 billion and operating profit of KRW 4.71 billion.
The recovery in 2026 has been more visible: first-quarter revenue of KRW 38.2 billion with operating profit of KRW 5.19 billion and owners' net income of KRW 5.21 billion, followed by second-quarter revenue of KRW 40.3 billion, operating profit of KRW 7.04 billion, and owners' net income of KRW 5.96 billion—two consecutive profitable quarters that moved past the fourth-quarter 2025 loss base.
Owners' net income over the trailing four quarters (3Q25 through 2Q26) totals roughly KRW 13.3 billion.
Annual operating margins fluctuated across the period—9.1% in 2022, 7.0% in 2023, 13.7% in 2024, and 9.7% in 2025—reflecting seasonality in cosmetic ingredients combined with shifting profit contributions from medical devices and health-supplement distribution.
The debt ratio improved from 41.1% in 2024 to 22.6% in 2025, indicating a healthier balance sheet. Notably, operating cash flow surged to KRW 19.5 billion in 2025 from KRW 4.6 billion in 2024, highlighting a gap between reported earnings and cash generation during the period.
Korea's cosmetic-ingredient industry continues moderate growth driven by expanding K-beauty exports and the rise of indie brands, though low entry barriers and abundant substitutes create structural price competition.
Recent trends include filaggrin-based skin barrier materials, exosome delivery technology, and slow-aging concepts, and the company showcased its next-generation exosome platform AIM-EX and filaggrin-based material DERMAFIL at the 'in-cosmetics Korea' event in July 2026.
The health-supplement market is viewed as a sustained growth area amid an aging population and rising health consciousness, benefiting the company's premium-brand distribution business.
In medical devices, demand for dental membranes tied to major domestic implant makers such as Osstem Implant has remained stable alongside growth in the dental implant market.
In terms of competitive positioning, the company is regarded as holding a dominant, roughly half-share lead in Korea's natural cosmetic-ingredient segment, though its business partially overlaps with cosmetics and supplement OEM/ODM peers such as Cosmax, Cosmax NBT, Kolmar BNH, and Kolmar Korea.
Overall, the company appears to be in a restructuring phase, shifting weight from the relatively lower-margin cosmetic ingredient business toward higher-margin medical device and health-supplement distribution segments.
The company has set a mid-to-long-term target of growing its Nestle Health Science brand distribution business to over KRW 100 billion in revenue by 2030, and this segment has shown sharp year-on-year growth in recent quarters.
In medical devices, both OssGuide and collagen products are reported to be in excess demand, prompting the company to begin capacity expansion.
The unveiling of new materials—filaggrin-based DERMAFIL, the exosome platform AIM-EX, customized collagen MULTI-FIT COLLAGEN, and plant-based PDRN—at the 'in-cosmetics Korea' event in July 2026 reflects an effort to technologically differentiate the cosmetic ingredient business.
However, the decision on how controlling shareholder Hyundai GF Holdings will dispose of its stake has been deferred under a regulatory exemption until 2027, meaning governance-related uncertainty could persist for some time given that the method of disposal (sale, merger, or other) remains undetermined.
Key items to watch include whether the profitability seen in the first and second quarters of 2026 extends through the second half, and whether seasonal factors again weigh on the fourth quarter.
The point at which the health-supplement distribution business reaches the reported breakeven revenue range (roughly KRW 35-40 billion) will also serve as an important marker for future earnings direction.
The stock trades at a level that appears discounted relative to the company's net asset value, with the price-to-book ratio below 1x suggesting the market is applying a cautious assessment relative to asset value.
Given the historically wide earnings volatility for this name (annual operating margins have swung between roughly 7% and 14%), the market's view on the durability of the recent profit recovery appears to be a factor embedded in the valuation.
On the dividend side, the company has maintained a per-share cash dividend, though assessing the sustainability of this policy relative to earnings size warrants monitoring future results.
Market commentary has also pointed to governance uncertainty—specifically, unresolved questions over how the controlling shareholder will handle its stake—as having weighed on institutional investor sentiment, a factor cited as a valuation discount that is not fully explained by earnings metrics alone.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
The medical device segment, though only about 15% of revenue, is a key profit source with operating margins above 30%, and both OssGuide and collagen products are reportedly in excess demand, prompting capacity expansion. A growing revenue mix from this segment holds potential to improve overall profitability. With Osstem Implant as a stable customer base, there also appears to be room to address overseas demand.
Exclusive domestic distribution of Nestle Health Science brands has shown large year-on-year revenue growth in recent quarters, and the company has set a target of expanding this business to over KRW 100 billion in revenue by 2030.
Access to the Hyundai Department Store Group's distribution network (department stores, duty-free, home shopping) is cited as a differentiating advantage versus peers. Continued revenue growth could bring the segment past breakeven scale.
Following an operating loss in fourth-quarter 2025, the company posted consecutive operating and owners' net profits in the first and second quarters of 2026, confirming an earnings recovery. The debt ratio also improved from 41.1% in 2024 to 22.6% in 2025, strengthening the balance sheet.
Operating cash flow rose substantially to KRW 19.5 billion in 2025 from the prior year, a further positive signal.
The decision on how controlling shareholder Hyundai GF Holdings will handle its stake (sale, merger, or otherwise) has been deferred until 2027, and past disappointment over unrealized tender-offer or sale expectations has reportedly left some institutional investors with losses, weighing on sentiment. Until this uncertainty is resolved, improvement in institutional demand may be delayed.
In 2025, solid results through the third quarter reversed sharply into a fourth-quarter loss, dragging full-year owners' net income down to just KRW 253 million. Annual operating margins have also fluctuated between 7.0% and 13.7% from 2022 to 2025.
Factors that have previously disrupted results—seasonality in the cosmetic ingredient business, costs related to the China subsidiary—cannot be ruled out from recurring.
While the company holds the No.1 share in Korea's natural cosmetic-ingredient market, natural materials account for less than 2% of overall cosmetics value, and abundant substitutes make high operating leverage difficult to expect, according to industry commentary.
Top-customer revenue concentration also remains at 35-40%, keeping customer concentration risk in place. Slower growth in this segment—still over 40% of total revenue—could weigh on overall results.
The direction of the controlling shareholder's stake disposal (sale, merger, etc.) remains unresolved, with a Fair Trade Commission exemption allowing the decision to be finalized by 2027. A resolution that conflicts with minority shareholder interests cannot be ruled out during this process.
Top-customer revenue concentration is reported at 35-40%, meaning order fluctuations from major customers could still significantly affect results. The medical device segment also carries relatively high dependence on a specific implant company.
Seasonality in cosmetic ingredients, the health-supplement distribution business not yet reaching breakeven, and cost burdens from new business investments (such as stem cell therapeutics) combine to create relatively high quarterly earnings volatility. A sharp swing into loss similar to the fourth quarter of 2025 cannot be ruled out from recurring.
The third-quarter report should be reviewed to see whether the expanding health-supplement distribution mix and medical device capacity additions are reflected in results.
This marks the deadline for controlling shareholder Hyundai GF Holdings' final decision on stake disposal (sale, merger, etc.); its impact on governance and minority shareholder value warrants monitoring.
The fourth-quarter and full-year 2026 results should be checked to see whether the seasonal loss pattern seen in 4Q25 recurs and how much full-year profit has recovered.
It is worth tracking whether the health-supplement distribution business reaches its reported breakeven revenue range (around KRW 35-40 billion) and the completion timeline for OssGuide and collagen capacity expansion.
Hyundai Bioland is in a transitional phase, shifting its center of gravity from traditional cosmetic ingredient business toward higher-margin medical devices and a health-supplement distribution business with meaningful growth potential.
The return to profit for two consecutive quarters in the first half of 2026 following a fourth-quarter 2025 loss can be read as a positive sign of earnings recovery, though the multi-year history of operating margins swinging between 7% and 14% calls for a cautious view on profit stability.
The matter of how controlling shareholder Hyundai GF Holdings will handle its stake remains deferred until 2027, and given that this governance uncertainty has long been cited by the market as a valuation discount factor, its progression warrants continued monitoring.
Whether the two growth pillars—medical devices and Nestle supplement distribution—scale past breakeven, and how the structural limits of the cosmetic ingredient business are managed, appear to be the key variables for future results.
On the balance sheet side, the declining debt ratio and improving operating cash flow suggest reasonable financial stability. Investors should maintain a balanced view by tracking both quarterly earnings releases and governance-related disclosures going forward.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.